VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Remazolam besylate
Approved
Small molecule
F
First Affiliated Hospital of Ningbo University
1
Indications
2
Total Trials
2
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Sedation
1 trial
Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis
Enrolling by invitation
·
F
First Affiliated Hospital of Ningbo University
·
Phase 4
·
NCT06731088
·
100 enrolled
Remimazolam Besylate
1 trial
Sedative Effect and Safety of Remimazolam Besylate in ARDS Patients
Recruiting
·
Z
Zhiming Jiang
·
Phase 4
·
NCT05758597
·
100 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for Remazolam besylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Remazolam besylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Remazolam besylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
First Affiliated Hospital of Ningbo University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Approved
[1]
Company
F
First Affiliated Hospital of Ningbo University
Related News